Table 1.
Main clinical characteristics and C‐trough DOAC levels in the cohort of patients
| Number | Age | Sex | Clinical indication | DOAC | Dose mg/d | Antiviral drugs | C‐trough (ng/mL) Pre‐hospitalization | C‐trough (ng/mL) In‐hospital | Δ % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 86 | M | NVAF | Dabigatran | 110 × 2 | Lopinavir/Ritonavir | 54 | 221 | +309.3 |
| 2 | 89 | F | NVAF | Apixaban | 2.5 × 2 | Lopinavir/Ritonavir | 71 | 420 | +491.5 |
| 3 | 74 | M | NVAF | Apixaban | 5 × 2 | Darunavir/Ritonavir | 112 | 185 | +65.2 |
| 4 | 69 | F | NVAF | Apixaban | 5 × 2 | Lopinavir/Ritonavir | 85 | 326 | +283.5 |
| 5 | 77 | M | VTE | Apixaban | 5 × 2 | Darunavir/Ritonavir | 78 | 142 | +82 |
| 6 | 73 | M | NVAF | Apixaban | 5 × 2 | Lopinavir/Ritonavir | 92 | 163 | +77.2 |
| 7 | 80 | F | NVAF | Edoxaban | 60 | Lopinavir/Ritonavir | 102 | 473 | +363.7 |
| 8 | 89 | M | NVAF | Edoxaban | 30 | Darunavir/Ritonavir | 25 | 112 | +348 |
| 9 | 85 | M | NVAF | Edoxaban | 30 | Darunavir/Ritonavir | 11 | 71 | +545.5 |
| 10 | 82 | M | NVAF | Rivaroxaban | 15 | Lopinavir/Ritonavir | 12 | 143 | +1091.7 |
| 11 | 77 | M | NVAF | Rivaroxaban | 20 | Lopinavir/Ritonavir | 16 | 505 | +3056.2 |
| 12 | 79 | F | NVAF | Rivaroxaban | 15 | Lopinavir/Ritonavir | 13 | 99 | +661.5 |